Heart rhythm risks from zanubrutinib or acalabrutinib in B-cell cancers
Treatments studied
Part of Heart & circulation clinical trials.
This trial looks at whether two targeted cancer drugs—zanubrutinib and acalabrutinib—increase the risk of a heart rhythm problem called atrial fibrillation. It is a safety study for people with chronic B-cell cancers who have already taken one of these drugs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a diagnosis of a chronic B-cell blood cancer (such as CLL or lymphoma).
- You have been treated with either zanubrutinib or acalabrutinib.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks for early signs of heart problems in people taking newer targeted blood cancer drugs called acalabrutinib or zanubrutinib. By using special blood tests, doctors hope to catch and manage heart issues before they become serious.
This trial tests a targeted therapy called acalabrutinib (a pill) against other standard treatments for chronic lymphocytic leukemia (CLL) in people who also have heart conditions. The goal is to see if acalabrutinib is a safer or more effective option for this group.
This trial tests a different targeted drug, acalabrutinib, for people with CLL or SLL who developed heart problems (like atrial fibrillation) while taking ibrutinib. The goal is to see if acalabrutinib can control the cancer without causing the same heart side effects.
This study watches for high blood pressure and irregular heartbeats in people with CLL who are starting a type of targeted therapy called a BTK inhibitor (acalabrutinib or zanubrutinib). Researchers will use a smartwatch and blood pressure cuff to monitor your heart health at home.
This study looks at whether starting certain blood cancer treatments (BTK inhibitors or others like venetoclax) affects heart rhythm. It focuses on people with specific blood cancers who are starting a new treatment, to check for new or worsening atrial fibrillation.
This trial studies acalabrutinib given after certain lymphoma treatments (like stem cell transplant or CAR T therapy) to help keep the lymphoma from coming back. It’s for people whose disease has shrunk (partial response) or fully gone away (complete response) after those treatments.
Hear when a new BTK Inhibitors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.